Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05926102 · ClinicalTrials.gov registry record · NA
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
A NA study of Prostate Cancer, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 5,000
- Enrollment target
- 1
- Study location
NCT05926102: Recruiting NA study of Prostate Cancer, sponsored by VA Office of Research and Development.
NCT05926102 is a NA study of Prostate Cancer that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 5,000 participants, above the 602-participant average among 735 other Prostate Cancer trials with a reported enrollment target (731% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05926102, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might help identify which men are at highest risk for prostate cancer. This study will examine whether a genetic test helps identify men at risk for significant prostate cancer while helping men who are at low risk for prostate cancer avoid unnecessary biopsies. If this genetic test proves beneficial, it will improve the way that healthcare providers screen male Veterans for prostate cancer.
Primary Outcome
Cases of csPCa will be abstracted from VA and survey data and defined using NCCN classifications of intermediate risk or higher: PSA 10 and/or Grade Group 2 and/or clinical T stage T2b
Conditions Studied
Interventions
- OTHER Usual care
- GENETIC Precision screening intervention
Study Locations (1)
Massachusetts
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2030-09-30 |
| Phase | NA |
What NCT05926102 shows while recruiting
NCT05926102 is an interventional study that assigns participants to a tested intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 602-participant average among 735 other Prostate Cancer trials with a reported enrollment target (731% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Usual care is the first listed.
NCT05926102 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05926102 about?
NCT05926102 is a clinical study titled "The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)". Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and whic...
What is the current status of trial NCT05926102?
This trial is currently recruiting. It is a NA study. The enrollment target is 5,000 participants. The study started on 2024-02-01. Estimated completion is 2030-09-30.
What conditions does trial NCT05926102 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05926102?
The interventions under investigation include: Usual care (OTHER), Precision screening intervention (GENETIC).
Who is sponsoring clinical trial NCT05926102?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05926102 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05926102's enrollment target sits among peer trials
5,000 12th of 735 higher than 722 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI